Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer.

[4] The most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.

[4][5] The most common adverse reactions for sotorasib used in combination with panitumumab include rash, dry skin, diarrhea, stomatitis, fatigue, and musculoskeletal pain.

[11] In the US, sotorasib is indicated for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by a Food and Drug Administration (FDA)-approved test, who have received at least one prior systemic therapy.

[4][9] In the EU, sotorasib, as monotherapy, is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.

[16] Researchers evaluated the efficacy of sotorasib in a study of 124 participants with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with disease progression after receiving an immune checkpoint inhibitor and/or platinum-based chemotherapy.

[17] The trial was conducted at 46 sites in 10 countries (Australia, Austria, Belgium, Canada, France, Germany, Japan, Korea, Switzerland, and the United States).

[17] The efficacy of using sotorasib, in combination with panitumumab, was evaluated in CodeBreaK 300 (NCT05198934), a randomized, open-label, controlled trial in participants with KRAS G12C-mutated mutated metastatic colorectal cancer who previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

[6][19] In January 2025, the FDA approved sotorasib, in combination with panitumumab, for the treatment of adults with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.